Literature DB >> 11225323

[Protection against influenza by genetically engineered vaccines].

T Abe1, H Takaku.   

Abstract

Viral vector recombinant DNA vaccines, so called genetically engineered vaccines, are introduced directly into cells to induce an antigen specific immune response. This is a new approach to vaccination that represents a new concept in immunotherapy, which attempts to induce a long-term effective, anti-specific, viral antigen immune response. These vaccines may also prove more potent than currently used vaccines when it comes to inducing cellular immune responses in addition to humoral immune response. In the case of influenza, an immune response with humoral characteristics was induced using an influenza hemagglutinin(HA) DNA vaccine. On the other hand, injection of influenza virus nucleoprotein(NP) induced a Th-1 type cellular immune response including CTL. Genetically engineered vaccines have the potential to effectively overcome the problem of unresponsiveness to currently used vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11225323

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  1 in total

1.  Development of DNA vaccines against hemolytic-uremic syndrome in a murine model.

Authors:  Alejandra V E Capozzo; Virginia Pistone Creydt; Graciela Dran; Gabriela Fernández; Sonia Gómez; Leticia V Bentancor; Carolina Rubel; Cristina Ibarra; Martín Isturiz; Marina S Palermo
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.